David A. Siegel Olema Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 148,500 shares of OLMA stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

148,500

Previous 180,800 17.87%

Holding current value

$1.61 Million

Previous $2.54 Million 33.71%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.95 - $16.62 $353,685 - $536,826	-32,300 Reduced 17.87%	148,500 $1.68 Million
Q4 2023 Feb 14, 2024	SELL	$10.53 - $17.14 $621,270 - $1.01 Million	-59,000 Reduced 24.6%	180,800 $2.54 Million
Q3 2023 Nov 14, 2023	SELL	$8.19 - $12.98 $9,009 - $14,278	-1,100 Reduced 0.46%	239,800 $2.96 Million
Q2 2023 Aug 14, 2023	BUY	$3.22 - $9.65 $112,700 - $337,750	35,000 Added 17.0%	240,900 $2.18 Million
Q1 2023 May 15, 2023	SELL	$2.55 - $4.97 $52,274 - $101,885	-20,500 Reduced 9.05%	205,900 $714,000

Q4 2022 Feb 14, 2023	SELL	$2.27 - $3.46 $358,887 - $547,026	-158,100 Reduced 41.12%	226,400 $554,000
Q3 2022 Nov 14, 2022	SELL	$2.85 - $5.88 $368,505 - $760,284	-129,300 Reduced 25.17%	384,500 $1.06 Million
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.61 $207,264 - $468,376	-101,600 Reduced 16.51%	513,800 $2.09 Million
Q1 2022 May 16, 2022	BUY	$3.89 - $9.43 $184,386 - $446,982	47,400 Added 8.35%	615,400 $2.62 Million
Q4 2021 Feb 14, 2022	BUY	$8.75 - $30.71 $4.89 Million - $17.2 Million	558,700 Added 6007.53%	568,000 $5.32 Million
Q3 2021 Nov 15, 2021	BUY	$22.96 - $30.13 $213,528 - $280,209	9,300 New	9,300 $256,000

Others Institutions Holding OLMA

# of Institutions

129

Shares Held

56M

Call Options Held

55K

Put Options Held

41.3K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $437M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account